Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'Weyer, C' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 65 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Weyer, C; Maggs, DG; Young, AA; Kolterman, OG
      Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improvedmetabolic control

      CURRENT PHARMACEUTICAL DESIGN
    2. Weyer, C
      Diabetes drug design - Preface

      CURRENT PHARMACEUTICAL DESIGN
    3. Weyer, C; Wolford, JK; Hanson, RL; Foley, JE; Tataranni, PA; Bogardus, C; Pratley, RE
      Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21-q23 and is associated with a common polymorphism in LMNA in Pima Indians

      MOLECULAR GENETICS AND METABOLISM
    4. Vozarova, B; Weyer, C; Hanson, K; Tataranni, PA; Bogardus, C; Pratley, RE
      Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion

      OBESITY RESEARCH
    5. Vozarova, B; Wang, J; Weyer, C; Tataranni, PA
      Comparison of two software versions for assessment of body-composition analysis by DXA

      OBESITY RESEARCH
    6. Weyer, C; Vozarova, B; Ravussin, E; Tataranni, PA
      Changes in energy metabolism in response to 48 h of overfeeding and fasting in Caucasians and Pima Indians

      INTERNATIONAL JOURNAL OF OBESITY
    7. Weyer, C; Tataranni, PA; Bogardus, C; Pratley, RE
      Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type a diabetes development

      DIABETES CARE
    8. Weyer, C; Salbe, AD; Lindsay, RS; Pratley, RE; Bogardus, C; Tataranni, PA
      Exaggerated pancreatic polypeptide secretion in Pima Indians: Can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans?

      METABOLISM-CLINICAL AND EXPERIMENTAL
    9. Weyer, C; Funahashi, T; Tanaka, S; Hotta, K; Matsuzawa, Y; Pratley, RE; Tataranni, PA
      Hypoadiponectinemia in obesity and type 2 diabetes: Close association withinsulin resistance and hyperinsulinemia

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    10. Pratley, RE; Weyer, C
      The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

      DIABETOLOGIA
    11. Gautier, JF; Wilson, C; Weyer, C; Mott, D; Knowler, WC; Cavaghan, M; Polonsky, KS; Bogardus, C; Pratley, RE
      Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes

      DIABETES
    12. Tschop, M; Weyer, C; Tataranni, PA; Devanarayan, V; Ravussin, E; Heiman, ML
      Circulating Ghrelin levels are decreased in human obesity

      DIABETES
    13. Weyer, C; Pratley, RE; Lindsay, RS; Tataranni, PA
      Relationship between birth weight and body composition, energy metabolism,and sympathetic nervous system activity later in life

      OBESITY RESEARCH
    14. Weyer, C; Sabat, R; Wissel, H; Kruger, DH; Stevens, PA; Prosch, S
      Surfactant protein A binding to cytomegalovirus proteins enhances virus entry into rat lung cells

      AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
    15. Weyer, C; de Souza, CJ
      Development of beta(3)-adrenoceptor agonists as antiobesity and antidiabetes drugs in humans: Current status and future prospects

      DRUG DEVELOPMENT RESEARCH
    16. Weyer, C; Pratley, RE; Snitker, S; Spraul, M; Ravussin, E; Tataranni, PA
      Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure

      HYPERTENSION
    17. Weyer, C; Tataranni, PA; Pratley, RE
      Insulin action and insulinemia are closely related to the fasting complement C3, hot not acylation stimulating protein concentration

      DIABETES CARE
    18. Weyer, C; Pratley, RE; Salbe, AD; Bogardus, C; Ravussin, E; Tataranni, PA
      Energy expenditure, fat oxidation, and body weight regulation: A study of metabolic adaptation to long-term weight change

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    19. Weyer, C; Foley, JE; Bogardus, C; Tataranni, PA; Pratley, RE
      Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance

      DIABETOLOGIA
    20. Weyer, C; Hanson, K; Bogardus, C; Pratley, RE
      Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight

      DIABETOLOGIA
    21. Weyer, C; Hanson, RL; Tataranni, PA; Bogardus, C; Pratley, RE
      A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance - Evidence for a pathogenic role of relative hyperinsulinemia

      DIABETES
    22. Weyer, C; Walford, RL; Harper, IT; Milner, M; MacCallum, T; Tataranni, PA; Ravussin, E
      Energy metabolism after 2 y of energy restriction: the Biosphere 2 experiment

      AMERICAN JOURNAL OF CLINICAL NUTRITION
    23. Weyer, C; Gautier, JF; Danforth, E
      Development of beta(3)-adrenoceptor agonists for the treatment of obesity and diabetes - An update

      DIABETES & METABOLISM
    24. Kimmerle, R; Heinemann, L; Heise, T; Bender, R; Weyer, C; Hirschberger, S; Berger, M
      Influence of continuous combined estradiol norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women

      MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
    25. Weyer, C; Pratley, RE
      Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians

      OBESITY RESEARCH
    26. Rave, K; Heise, T; Weyer, C; Sawicki, P; Heinemann, L
      Measurement of insulin sensitivity: Influence of potassium supply during euglycaemic glucose clamps in healthy volunteers

      EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    27. Heinemann, L; Sinha, K; Weyer, C; Loftager, M; Hirschberger, S; Heise, T
      Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

      DIABETIC MEDICINE
    28. Weyer, C; Snitker, S; Rising, R; Bogardus, C; Ravussin, E
      Determinants of energy expenditure and fuel utilization in man: effects ofbody composition, age, sex, ethnicity and glucose tolerance in 916 subjects

      INTERNATIONAL JOURNAL OF OBESITY
    29. Rave, K; Heinemann, L; Puhl, L; Gudat, U; Woodworth, JR; Weyer, C; Heise, T
      Premixed formulations of insulin lispro

      DIABETES CARE
    30. Weyer, C; Bogardus, C; Mott, DM; Pratley, RE
      The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

      JOURNAL OF CLINICAL INVESTIGATION
    31. Weyer, C; Bogardus, C; Pratley, RE
      Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes

      DIABETES
    32. Weyer, C; Bogardus, C; Pratley, RE
      Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance

      DIABETES
    33. Weyer, C; Snitker, S; Bogardus, C; Ravussin, E
      Energy metabolism in African Americans: potential risk factors for obesity

      AMERICAN JOURNAL OF CLINICAL NUTRITION
    34. RAVE K; HEISE T; WEYER C; HERRNBERGER J; BENDER R; HIRSCHBERGER S; HEINEMANN L
      INTRAMUSCULAR VERSUS SUBCUTANEOUS INJECTION OF SOLUBLE AND LISPRO INSULIN - COMPARISON OF METABOLIC EFFECTS IN HEALTHY-SUBJECTS

      Diabetic medicine
    35. WEYER C; LINKESCHOWA R; HEISE T; GIESEN HT; SPRAUL M
      IMPLICATIONS OF THE TRADITIONAL AND THE NEW ACSM PHYSICAL-ACTIVITY RECOMMENDATIONS ON WEIGHT-REDUCTION IN DIETARY TREATED OBESE SUBJECTS

      International journal of obesity
    36. HEISE T; WEYER C; SERWAS A; HEINRICHS S; OSINGA J; ROACH P; WOODWORTH J; GUDAT U; HEINEMANN L
      TIME-ACTION PROFILES OF NOVEL PREMIXED PREPARATIONS OF INSULIN LISPROAND NPL INSULIN

      Diabetes care
    37. HEINEMANN L; WEYER C; RAUHAUS M; HEINRICHS S; HEISE T
      VARIABILITY OF THE METABOLIC EFFECT OF SOLUBLE INSULIN AND THE RAPID-ACTING INSULIN ANALOG INSULIN ASPART

      Diabetes care
    38. SINHA K; WEYER C; LOFTAGER M; HIRSCHBERGER S; HEISE T; HEINEMANN L
      TIME-ACTION PROFILE OF THE SOLUBLE, FATTY-ACID ACYLATED LONG-ACTING INSULIN ANALOG NN304

      Diabetologia
    39. WEYER C; TATARANNI PA; SNITKER S; DANFORTH E; RAVUSSIN E
      IMPROVEMENT IN INSULIN ACTION AND INCREASE IN FAT OXIDATION FOLLOWINGTREATMENT WITH CL-316.243, A SELECTIVE BETA(3)-ADRENOCEPTOR AGONIST IN HUMANS

      Diabetologia
    40. KATZ JR; WEYER C; RAVE K; COPPACK SW; YUDKIN J
      NO REGIONAL DIFFERENCES IN THE SENSITIVITY OF THE SUBCUTANEOUS ADIPOSE-TISSUE TO THE ANTI-LIPOLYTIC EFFECT OF INSULIN OBESE, DIABETIC AND NONDIABETIC WOMEN

      Diabetologia
    41. HEINEMANN L; RAVE K; WEYER C; PAUL L; GUDAT U; ROACH P; WOODWORTH J; HEISE T
      PREMIXED FORMULATIONS OF INSULIN LISPRO - ACTIVITY PROFILES IN TYPE-1DIABETIC-PATIENTS

      Diabetologia
    42. WEYER C; TATARANNI PA; SNITKER S; DANFORTH E; RAVUSSIN E
      INCREASE IN INSULIN ACTION AND FAT OXIDATION AFTER TREATMENT WITH CL-316,243, A HIGHLY SELECTIVE BETA(3)-ADRENOCEPTOR AGONIST IN HUMANS

      Diabetes
    43. WEYER C; TATARANNI PA; DANFORTH E; RAVUSSIN E
      THE EFFECTS OF 8 WEEKS OF TREATMENT WITH THE SELECTIVE BETA(3)-ADRENOCEPTOR AGONIST CL-316.243 ON INSULIN ACTION IN MAN

      Diabetes
    44. WEYER C; KATZ J; RAVE K; COPPACK S; YUDKIN J
      RELATIONSHIP BETWEEN THE ACTION OF INSULIN ON SC ADIPOSE-TISSUE LIPOLYSIS AND ON WHOLE-BODY GLUCOSE DISPOSAL IN OBESE WOMEN

      Diabetes
    45. RAVE K; HEISE T; WEYER C; HERRNBERGER J; BENDER R; HIRSCHBERGER S; HEINEMANN L
      INTRAMUSCULAR VS SUBCUTANEOUS INJECTION OF REGULAR INSULIN AND INSULIN LISPRO - COMPARISON OF THE METABOLIC EFFECTS IN HEALTHY-SUBJECTS

      Diabetes
    46. HEISE T; RAVE K; WEYER C; PAUL L; GUDAT U; ROACH P; WOODWORTH J; HEINEMANN L
      PREMIXED FORMULATIONS OF INSULIN LISPRO - ACTIVITY PROFILES IN TYPE-1DIABETIC-PATIENTS

      Diabetes
    47. HEINEMANN L; WEYER C; RAVE K; STIEFELHAGEN O; RAUHAUS M; HEISE T
      COMPARISON OF THE TIME-ACTION PROFILES OF U40-REGULAR AND U100-REGULAR HUMAN INSULIN AND THE RAPID-ACTING INSULIN ANALOG B28 ASP

      EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    48. WEYER C; MOHRKAHALY S; ERBEL R; MEYER J
      FOLLOW-UP OF PATIENTS WITH CHRONIC SEVERE AORTIC REGURGITATION TREATED WITH ACE-INHIBITOR

      Zeitschrift fur Kardiologie
    49. WEYER C; HEISE T; HEINEMANN L
      INSULIN ASPART IN A 30 70-PREMIXED FORMULATION - PHARMACODYNAMIC PROPERTIES OF A RAPID-ACTING INSULIN ANALOG IN STABLE MIXTURE/

      Diabetes care
    50. WEYER C
      REPORT FROM A MEMBER AWARDED AN EASD-BAYER TRAVEL FELLOWSHIP FOR YOUNG SCIENTISTS 1997

      Diabetologia
    51. NEOPHYTOU P; WEYER C; LUPPI P; JORNS A; BOTTINO R; CAMPBELLTOFTE J; COHEN O; GURNIAK M; HUOTARI MA; JENSEN P; KARLSSON M; LEFEBVRE V; MABLEY J; MORGENTHALER N; MUELLER R; OHARTE F; RUDICH A; SOULIS T; UTRIAINEN T
      REPORT ON THE THIRD EASD SCIENTISTS TRAINING COURSE

      Diabetologia
    52. HEINEMANN L; WEYER C; RAUHAUS M; HEINRICHS S; HEISE T
      VARIABILITY OF THE METABOLIC EFFECT OF SC INJECTED REGULAR INSULIN AND THE RAPID ACTING INSULIN-ANALOG B28ASP

      Diabetologia
    53. MAGNUSSON K; SIEBECKE H; HEISE T; WEYER C; HEINEMANN L; SAWICKI PT
      BLUNTED VASODILATORY EFFECT OF INSULIN IN HYPERTENSIVE OBESE SUBJECTS

      Diabetologia
    54. WEYER C; HEISE T; HEINEMANN L
      PREMIXED FORMULATION OF B28ASP AND NPH-INSULIN - PHARMACODYNAMIC PROPERTIES OF A 30 70-STABLE MIXTURE/

      Diabetologia
    55. RAVE K; WEYER C; STIEFELHAGEN O; RAUHAUS M; HEISE T; HEINEMANN L
      COMPARISON OR THE METABOLIC-ACTIVITY OF THE INSULIN ANALOG B28ASP WITH SOLUBLE INSULIN IN U40 AND U100 CONCENTRATION

      Diabetologia
    56. HEISE T; WEYER C; SERWAS A; HEINRICHS S; OSINGA J; ROACH P; WOODWORTH J; HEINEMANN L
      TIME-ACTION PROFILES OF PREMIXED FORMULATIONS OF INSULIN LISPRO AND NPL-INSULIN

      Diabetologia
    57. HEINEMANN L; WEYER C; STOFFELS M; SCHADEN U; HEISE T
      RELIABLE BLOOD-GLUCOSE MEASUREMENT WITH THE APEC GLUCOSE ANALYZER

      Diabetologia
    58. WEYER C; HEISE T; HEINEMANN L
      PREMIXED FORMULATION OF B28ASP AND NPL-INSULIN - PHARMACODYNAMIC PROPERTIES OF A 30 70-STABLE MIXTURE/

      Diabetes
    59. HEISE T; WEYER C; SERWAS A; HEINRICHS S; OSINGA J; ROACH P; WOODWORTH J; HEINEMANN L
      TIME-ACTION PROFILES OF PREMIXED FORMULATIONS OF INSULIN LISPRO AND NPL-INSULIN

      Diabetes
    60. HEISE T; WEYER C; RAUHAUS M; STIEFELHAGEN O; HEINEMANN L
      VARIABILITY OF THE METABOLIC EFFECT OF SC INJECTED REGULAR INSULIN AND THE RAPID ACTING INSULIN-ANALOG B28ASP

      Diabetes
    61. MAGNUSSON K; SIEBECKE H; HEISE T; WEYER C; SAWICKI P
      BLUNTED VASODILATORY EFFECT OF INSULIN IN HYPERTENSIVE OBESE SUBJECTS

      Diabetes
    62. REDECKER P; WEYER C; GRUBE D
      RAT AND GERBIL PINEALOCYTES CONTAIN THE SYNAPTOSOMAL-ASSOCIATED-PROTEIN-25 (SNAP-25)

      Journal of pineal research
    63. WEYER C; HEISE T; KAPITZA C; STARKE AAR; HEINEMANN L
      DURATION OF ACTION OF THE INSULIN ANALOG B28ASP IN COMPARISON TO REGULAR INSULIN

      Diabetologia
    64. BEYER J; SCHWARTZ S; BARZEN G; RISSE G; DULLENKOPF K; WEYER C; SIEGERT W
      USE OF AMPHOTERICIN-B AEROSOLS FOR THE PREVENTION OF PULMONARY ASPERGILLOSIS

      Infection
    65. BEYER J; BARZEN G; RISSE G; WEYER C; MIKSITS K; DULLENKOPF K; HUHN D; SIEGERT W
      AEROSOL AMPHOTERICIN-B FOR PREVENTION OF INVASIVE PULMONARY ASPERGILLOSIS

      Antimicrobial agents and chemotherapy


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/02/20 alle ore 23:16:31